The Jaffré Group focuses on deciphering the molecular mechanisms underlying congenital heart defects and cardiomyopathies in children with rare genetic disorders. We use human induced-pluripotent stem cells (iPSCs) as a developmental and disease model combined with cardiac directed differentiation, genome editing (CRISPR), multi-omics, 3D organoids and engineered heart tissues. Our ultimate goal is to discover new therapeutic approaches for children with rare genetic disorders.